GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
03 Mar 2025 07:00 AM
RNS
ANCHOR results presented at 2025 AAAAI
03 Mar 2025 07:00 AM
RNS
Transaction in Own Shares
28 Feb 2025 07:00 AM
RNS
Transaction in Own Shares
27 Feb 2025 10:00 AM
RNS
GSK publishes Annual Report 2024
27 Feb 2025 07:00 AM
RNS
Transaction in Own Shares
26 Feb 2025 04:00 PM
RNS
Director/PDMR Shareholding
26 Feb 2025 07:00 AM
RNS
Transaction in Own Shares
25 Feb 2025 07:00 AM
RNS
Transaction in Own Shares
24 Feb 2025 07:05 AM
RNS
GSK completes acquisition of IDRx, Inc.
24 Feb 2025 07:00 AM
RNS
GSK plc commences share buyback programme
21 Feb 2025 07:00 AM
RNS
Directorate Change
21 Feb 2025 07:00 AM
RNS
Director/PDMR Shareholding
21 Feb 2025 07:00 AM
RNS
Director/PDMR Shareholding
21 Feb 2025 07:00 AM
RNS
Director/PDMR Shareholding
21 Feb 2025 07:00 AM
RNS
Director/PDMR Shareholding
21 Feb 2025 07:00 AM
RNS
Director/PDMR Shareholding
21 Feb 2025 07:00 AM
RNS
Director/PDMR Shareholding
20 Feb 2025 07:00 AM
RNS
Nucala COPD submission accepted in China
17 Feb 2025 07:00 AM
RNS
GSK 5-in-1 meningitis vaccine approved by US FDA
13 Feb 2025 03:30 PM
RNS
Director/PDMR Shareholding
11 Feb 2025 03:30 PM
RNS
Director/PDMR Shareholding
05 Feb 2025 07:00 AM
RNS
Final Results
03 Feb 2025 04:48 PM
RNS
Total Voting Rights
28 Jan 2025 07:05 AM
RNS
Depemokimab dual filing in China and Japan
28 Jan 2025 07:00 AM
RNS
EMA accepts two submissions for depemokimab
27 Jan 2025 07:05 AM
RNS
EMA accept review Shingrix syringe presentation
20 Jan 2025 07:00 AM
RNS
Jemperli expanded approval in the EU
16 Jan 2025 03:30 PM
RNS
Director/PDMR Shareholding
15 Jan 2025 03:30 PM
RNS
Director/PDMR Shareholding
14 Jan 2025 03:30 PM
RNS
Director/PDMR Shareholding
13 Jan 2025 03:30 PM
RNS
Director/PDMR Shareholding
13 Jan 2025 07:00 AM
RNS
GSK enters agreement to acquire IDRx, Inc.
10 Jan 2025 07:00 AM
RNS
Shingrix fully liquid accepted for US FDA review
07 Jan 2025 07:00 AM
RNS
GSK ADC gets FDA breakthrough therapy designation
03 Jan 2025 07:00 AM
RNS
GSK’s Nucala approved in China for use in CRSwNP
02 Jan 2025 03:00 PM
RNS
Total Voting Rights
23 Dec 2024 03:30 PM
RNS
Director/PDMR Shareholding
20 Dec 2024 09:00 AM
RNS
Block Listing Application
20 Dec 2024 07:00 AM
RNS
Headline results from phase III FIRST trial
16 Dec 2024 07:11 AM
RNS
Jemperli receives US FDA breakthrough designation
16 Dec 2024 07:05 AM
RNS
EMA grants PRIME Designation for GSK’227
16 Dec 2024 07:00 AM
RNS
Jemperli receives positive CHMP opinion
12 Dec 2024 03:30 PM
RNS
Director/PDMR Shareholding
09 Dec 2024 06:29 PM
RNS
Overall survival data presented for Blenrep
09 Dec 2024 07:05 AM
RNS
Blenrep combination China filing acceptance
09 Dec 2024 07:00 AM
RNS
Nucala COPD submission accepted by US FDA
05 Dec 2024 07:00 AM
RNS
Zhifei China collaboration revised and extended
02 Dec 2024 03:30 PM
RNS
Director/PDMR Shareholding
02 Dec 2024 03:00 PM
RNS
Total Voting Rights
27 Nov 2024 07:00 AM
RNS
GSK liquid meningitis vaccine authorised in EU

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

GSK share price launched at 346p in 1989. 

UK 100

Latest directors dealings